11 HRT Misconceptions That Primary Care Doctors Still Repeat in Consultation That Harm Women
The number of women who've been told 'the risks outweigh the benefits' by a doctor who spent four minutes on the topic — without ever being shown the actual numbers — is genuinely heartbreaking. This isn't about pressuring anyone into HRT. It's about making sure every woman gets to make her choice on accurate information, not a misread study from 2002.
Learn more about Rose →"HRT causes breast cancer" — stated as settled fact
The absolute risk increase associated with combined HRT is small and context-dependent — comparable to, or lower than, the risk associated with drinking two units of alcohol per day or having a BMI over 30. The original WHI study that triggered this fear was conducted in older women (average age 63) using oral conjugated equine oestrogen plus medroxyprogesterone acetate — a synthetic progestogen no longer considered first-line. More recent data, including the large-scale re-analysis by Collaborative Group on Hormonal Factors in Breast Cancer (2019), shows that risk varies significantly by HRT type, duration, route of delivery, and individual baseline risk — nuance that a blanket warning erases entirely.
"You should only take HRT for two years maximum"
There is no universal two-year cut-off supported by current evidence or endorsed by the British Menopause Society, the Menopause Society (formerly NAMS), or NICE guidelines. This figure appears to be a holdover from post-WHI caution that was never intended as a hard limit for all women. Duration of HRT use should be an individualised decision based on symptom burden, quality of life, risk profile, and ongoing review — not a default timer.
"HRT isn't appropriate if you're still having periods"
Perimenopause — the years of hormonal fluctuation before periods stop — is precisely when many women experience the most disruptive symptoms, and when HRT can be most beneficial. NICE guidelines (NG23, updated 2019) explicitly support offering HRT to women in perimenopause with troublesome symptoms. Withholding treatment until menopause is confirmed (12 months without a period) leaves women undertreated during some of their hardest years.
"You don't need the progesterone component if your symptoms aren't bad"
Progesterone (or a progestogen) is not prescribed based on symptom severity — it is prescribed to protect the endometrium (uterine lining) in women who have a uterus. Without it, oestrogen-only HRT significantly increases the risk of endometrial hyperplasia and endometrial cancer. Symptom severity is completely irrelevant to this physiological requirement.
"HRT increases your risk of heart disease"
This is the opposite of what current evidence shows for most women who start HRT before age 60 or within ten years of menopause. The 'timing hypothesis' — well-supported by the Nurses' Health Study, KEEPS trial, and subsequent meta-analyses — demonstrates that oestrogen started in the early menopause window is cardioprotective, not harmful. The elevated cardiovascular risk seen in the WHI was in an older cohort starting treatment more than a decade post-menopause, a context that does not apply to most women seeking HRT.
"Blood tests are needed to confirm menopause before starting HRT"
NICE guidelines are clear: in women over 45 with typical menopausal symptoms, a clinical diagnosis is sufficient and blood tests are not routinely required before starting HRT. FSH levels fluctuate significantly during perimenopause and a single reading is unreliable as a diagnostic tool. Requiring blood tests before prescribing creates an unnecessary barrier that delays treatment for symptomatic women.
"Bioidentical hormones from compounding pharmacies are safer than regulated HRT"
Unregulated compounded 'bioidentical' hormones have not been tested in large-scale clinical trials and their purity, potency, and dosing consistency are not subject to the same regulatory oversight as licensed HRT products. Regulated body-identical hormones — 17-beta oestradiol and micronised progesterone — are already available on prescription and are structurally identical to what compounding pharmacies produce. The safer, evidence-backed version of body-identical HRT is already in the pharmacy.
"HRT is contraindicated if you've had a blood clot"
Oral oestrogen does carry an increased risk of venous thromboembolism (VTE), which is why it is generally avoided in women with a history of blood clots. However, transdermal oestrogen (patches, gels, sprays) does not carry the same hepatic first-pass effect and is not associated with increased VTE risk in current evidence. Many women with a history of blood clots can safely use transdermal HRT — this requires specialist input, but an outright contraindication for all HRT is not accurate.
"Antidepressants are a reasonable first-line alternative to HRT for mood symptoms"
Low mood, anxiety, and irritability in perimenopause and menopause are primarily driven by hormonal fluctuation — not a serotonin deficit. Prescribing SSRIs or SNRIs as a default first response, without considering hormone therapy, treats the wrong mechanism. While antidepressants have a role for some women — particularly those with a personal or family history of clinical depression — they do not address the underlying hormonal cause and can carry their own side-effect burden including sexual dysfunction and weight changes.
"HRT is not suitable for women over 60"
Age alone is not a contraindication for HRT. While the benefit-risk calculation does shift as women age — particularly regarding cardiovascular and breast cancer risk — women over 60 can still be appropriate candidates for HRT, particularly those with ongoing symptoms, early menopause history, or bone health concerns. The British Menopause Society advises that decisions should be individualised and not based on age thresholds alone. Women are still being told at 61 that they've 'missed the window' when that conversation should be far more nuanced.
"Genitourinary symptoms are just part of ageing — HRT won't help"
Genitourinary Syndrome of Menopause (GSM) — which includes vaginal dryness, urinary urgency, recurrent UTIs, and painful sex — is directly caused by oestrogen depletion and responds well to localised oestrogen treatment. Vaginal oestrogen is low-dose, minimally absorbed systemically, and is not subject to the same risk considerations as systemic HRT, meaning it is appropriate for the vast majority of women including many who cannot take systemic therapy. Dismissing these symptoms as inevitable ageing, rather than a treatable hormonal consequence, causes significant and unnecessary impact on quality of life and sexual health.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.